{"id":1738,"date":"2020-07-15T13:19:45","date_gmt":"2020-07-15T11:19:45","guid":{"rendered":"http:\/\/medsper-2019.uniroma2.it\/?page_id=1738"},"modified":"2020-07-15T13:19:45","modified_gmt":"2020-07-15T11:19:45","slug":"eccellenza-t-o-r","status":"publish","type":"page","link":"https:\/\/www-2026.medsper.uniroma2.it\/?page_id=1738","title":{"rendered":"Eccellenza T.O.R."},"content":{"rendered":"\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

link al sito www.centrotor.uniroma2.it<\/a><\/span><\/p>\n

\u00a0<\/p>\n

TITOLO:<\/strong> <\/span>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Torvergata Oncoscience Research (TOR) \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

CAMPO D\u2019AZIONE:\u00a0<\/span>\u00a0\u00a0 <\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Public Engagement (g) + Sperimentazione Clinica e Tutele della Salute (e) + Open Science (i)<\/p>\n<\/td>\n<\/tr>\n

\n

A. ISTITUZIONE:<\/strong>\u00a0<\/span> \u00a0 \u00a0 \u00a0 \u00a0<\/p>\n

\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Universita’ di Roma Tor Vergata<\/p>\n<\/td>\n<\/tr>\n

\n

B. DIPARTIMENTO o DIPARTIMENTI DI RIFERIMENTO:<\/span>
<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Dipartimento di MEDICINA SPERIMENTALE<\/p>\n<\/td>\n<\/tr>\n

\n

C. EVENTUALI AREE SCIENTIFICHE DI RIFERIMENTO DEL CASO STUDIO: <\/strong><\/span><\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Oncologia Precisione, Editoria scientifica<\/p>\n<\/td>\n<\/tr>\n

\n

D. PERSONALE ACCADEMICO DI RIFERIMENTO: <\/strong><\/span>G. Melino, M. Piacentini, G. Tisone, G. Novelli, E. Candi, M. Agostini, F. Bernassola, S. Grelli, N. Rosato, I. Amelio, A. Mauriello<\/p>\n<\/td>\n<\/tr>\n

\n

E. PAROLE CHIAVE:\u00a0\u00a0 <\/strong><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Giornali Scientifici, Oncologia, Medicina Precisione, Conferenze Scientifiche, Biochimica, Mutazioni, p53<\/p>\n<\/td>\n<\/tr>\n

\n

F. DESCRIZIONE DETTAGLIATA DEL CASO STUDIO<\/strong><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Fondato nel 2018 con la costituzione del nuovo Dipartimento di Medicina Sperimentale, come CENTRO DI ECCELLENZA INTERDIPARTIMENTALE con aspirazioni internazionali di lunga durata, ha coinvolto risorse umane selettive di 4 dipartimenti universitari collegate a forti realt\u00e0 dell’area Romana (3 IRCCS) ed internazionale per lo sviluppo della ricerca di base e traslazionale nell’ ONCOLOGIA DI PRECISIONE.<\/p>\n

Il Direttore \u00e8 il prof G. Melino.<\/p>\n

Il vice-Direttore \u00e8 il prof M. Piacentini.<\/p>\n

MISSIONE & SCOPO<\/strong>:<\/span> Il TOR ha i seguenti scopi:<\/p>\n

Coordinare le forze<\/u>nell\u2019Universit\u00e0 di Roma Tor Vergata per sviluppare la ricerca di base e traslazionale in Oncologia di Precisione<\/u>.<\/p>\n

Creare una piattaforma tecnologica<\/u> e sperimentale di Oncologia sperimentale.<\/p>\n

Disseminare i risultati e le informazioni scientifiche attraverso congressi, convegni, editoria scientifica<\/u>.<\/p>\n

Sviluppare l’addestramento<\/u>della futura generazione di scienziati attraverso Master, Dottorato, post-doc.<\/p>\n

Favorire reti internazionali di traslazione<\/u> clinica, trasferimento tecnologico.<\/p>\n

SCIENTIFIC ADVISORY BOARD<\/strong>:<\/span> (SAB)\u00a0 Il TOR ha sede centrale nel Dipartimento di Medicina Sperimentale (Prof G. Melino, E. Candi, N. Rosato, A. Mauriello, F. Bernassola, M. Agostini, I. Amelio, S. Grelli) ma coinvolge il Dipartimento di Biologia (M. Piacentini), il Dipartimento di Chirurgia (G. Tisone) e il Dipartimento di Biomedicina e Prevenzione (G. Novelli).\u00a0 Il TOR e’ guidato dal SAB costituito da:<\/p>\n

Aaron CIECHANOVER<\/u><\/em><\/strong>, Nob<\/span>el Prize for Chemistry 2004 for the discovery of the of ubiquitin-mediated protein degradation, Albert Lasker Award for Basic Medical Research in 2000. He works at theTechnion \u2013 Israel Institute of Technology in Haifa. President of SAB.<\/p>\n

Tak Wah MAK<\/u><\/em><\/strong>, awarded the Emil von Behring Prize in 1988 and the Paul Ehrlich and Ludwig Darmstaedter Prize in 2004 for the discovery of the T-cell receptor. Elucidated the function of CTLA-4, paving the road for Immunotherapy and Checkpoint inhibition as potential anti-cancer therapies; and recently developed drugs modulating cancer metabolism. Works at Univ Toronto, Canada.<\/span><\/p>\n

Yufang SHI<\/u><\/em><\/strong>, Dean, Medical School, Kunming University of Science and Technology; Director, Institutes for Tra<\/span>nslational Medicine of Soochow University; Vice President, The First Affiliated Hospital of Soochow University; Professor, Rutgers Cancer Institute of New Jersey, USA. Expert on Activation-Induced Cell Death in T-cells and on immune regulation and on MSCs and tumor microenvironment. Works primarily in Soochow and Shanghai, China. Secretary of SAB.<\/p>\n<\/td>\n<\/tr>\n

\n

G. DESCRIZIONE DETTAGLIATA DELL\u2019IMPATTO NEL PERIODO 2015 \u2013 2019<\/strong><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

ATTIVITA’ EDITORIALE SCIENTIFICA<\/strong>:<\/span>\u00a0 Il TOR \u00e8 sede centrale dei seguenti giornali scientifici:<\/p>\n

Cell Death Differentiation<\/u><\/em><\/strong>, www.nature.com\/cdd,\u00a0 impact factor 10.5<\/p>\n

Cell Death Disease<\/u><\/em><\/strong>, www.nature.com\/cddis, impact factor 6.1<\/p>\n

Cell Death Discovery<\/u><\/em><\/strong>, www.nature.com\/cddiscov, impact factor 4.2<\/p>\n

ATTIVITA’ CONFERENZE SCIENTIFICHE<\/strong>:<\/span>\u00a0 Il TOR ha organizzato i seguenti convegni scientifici (vengono riportati solo quelli 2018-19):<\/p>\n

CDDConference 2018 Cambridge, UK<\/u><\/em> on \u201cGenes vs Environment in Cancer\u201d. Speakers included Tak Mak (Toronto), Karen Vousden (London), ScoK Lowe (New York), Doug Green (Memphis), Bachir Al Affar (Montreal), Maria Soengas (Madrid), Pascal Meier (London), Charlie Swanton (London).<\/p>\n

CDDConference 2018 Shanghai<\/u><\/em>, China on the topic \u201cCell Death & StemCells\u201d. Speaker’s list included Tak Mak (Toronto), Hans-Uwe SImon (Bern), Weidong Han (Beijing), Yongguang Yang (Jilin), Songtao Shi (Philadelphia), Antonio Uccelli (Genoa), Guoping Fan (Los Angeles), Yufang Shi (Soochow).<\/p>\n

Symposium \u201cReproducibility in Biomedical Research<\/u><\/em>\u201d, 22-05-2018, Accademia Lincei, Rome.<\/p>\n

Symposium \u201cThe Scientfic Research in Italy<\/u><\/em>\u201d, 25-06-2018 in Rome Tor Vergata, hosting Annette Schavan (former German Minister Education-Research), Pierluigi Nicotera (Director DZNE), Alison Abbot (Editor Nature).<\/p>\n

CDDConference 2019 Cambridge, UK<\/em> on \u201cCancer, Immunity & Inflamma<on\u201d. Speakers included the NobelLaurate Greg Winter (Cambridge), M Karin (San Diego), J Chipuk (NY), VM Dixit (San Francisco), C Prives (New York), P Vandenabeele (Gent), Ying Wang (Shanghai), X Wang (Beijing).<\/p>\n

CDDConference 2019 Wuxi, China<\/u><\/em> on \u201cNew Drug Discovery\u201d. Speaker’s list included Michel Sadelain (NY), WillemFibbe (Leiden), Guoping Fan (Los Angeles), Tak Mak (Toronto), Naoto Hirano (Toronto), Francesco Dazzi (London), Ruibao Ren (Shanghai), Yufang Shi (Soochow)<\/p>\n

CDDRetreat 2018 in Capri, Italy<\/u><\/em>. Speaker’s list included the Nobel Laureate Aaron Ciechanover (Haifa), Tak W Mak (Toronto), Carlo Croce (Columbus, US), Ashok Venkitaraman (Cambridge), Xin Lu (Oxford), Jerry Chipuk (NY), Doug Green (Memphis), Michal Karin (San Diego), Yufang Shi (Shanghai).<\/p>\n

Symposium \u201cScientific Integrity in Academic Research<\/u><\/em>\u201d, 27-03-2019 Rome Tor Vergata, hosting Walter Ricciardi (ISS), Ernesto Carafoli (Lincei), Paola Balducci (Magistrate Superior Council),Gennaro Ciliberto (FiSV).<\/p>\n

Symposium \u201cGenes vs Environment<\/u><\/em>\u201d 23-09-2019 Rome Tor Vergata, Villa Mondragone, hosting Bruce Beutler (Nobel Laureate 2011), Michele Carbone (Honolulu), Erino Rendina (Rome), Francesco Facciolo (Rome).<\/p>\n

ATTIVITA’ ADDESTRAMENTO SCIENTIFICO<\/strong>:<\/span>\u00a0 Il TOR \u00e8 sede centrale dei seguenti corsi:<\/p>\n

Dottorato Ricerca<\/u><\/em> in Biochimica e Biologia Molecolare,\u00a0 coordinatore E. Candi<\/p>\n

Master<\/u><\/em> in Nutrizione e Cosmesi,\u00a0 coordinatore E. Candi<\/p>\n

ATTIVITA’ CONVENZIONI COLLABORAZIONE SCIENTIFICA ROMA<\/strong>:<\/span>\u00a0 Il TOR ha stipulato ed attivato le seguenti convenzioni\u00a0 dei collaborazione scientifica:<\/p>\n

Istituto Dermopatico Immacolata, IDI-IRCCS, Ospedale ed Istituto Dermatologia. Prof Gianni Russo.<\/p>\n

Istituto Regina Elena, IRE-IRCCS, Ospedale Nazionale del Cancro. Prof Gennaro CIliberto.<\/p>\n

Istituto Nazionale Malattie Infettive Spallanzani, INMI-IRCCS, Malattie Infettive. Prof Giuseppe Ippolito.<\/p>\n

Ospedale San Carlo Nancy, Urologia e Chirurgia Urologica. Prof Pierluigi Bove.<\/p>\n

ATTIVITA’ CONVENZIONI COLLABORAZIONE SCIENTIFICA INTERNAZIONALI<\/strong>:\u00a0<\/span> Il TOR ha stipulato ed attivato le seguenti convenzioni\u00a0 dei collaborazione scientifica internazionali:<\/p>\n

Indivumed GmbH<\/u><\/em><\/strong>(https:\/\/www.indivumed.com), fondata nel 2002 con oltre 100 milioni di risorse, dedicata all’Oncologia di Precisione in una rete internazionale di 18 nazioni, di cui il TOR \u00e8 l’hub Italiano.<\/p>\n

Onconetics Pharmaceuticals Inc.<\/u><\/em><\/strong> (www.onconetics.com), San Francisco California USA, fondata nel 2016 ha stabilito una convenzione col TOR ed aperto un laboratorio all’interno del TOR.<\/p>\n

Oncology Alliance for Individualized Medicine (Onco AI-Med)<\/u><\/em><\/strong>, fondata a Gennaio 2020 attraverso una rete di collaborazione tra Georgetown University, Washington DC (sede centrale), Oxford University, altri centri di ricerca oncologici in Korea, Germania, Spagna, Irlanda, Brasile, Singapore, Svezia ed il TOR come unico hub Italiano per lo sviluppo e scambio di ricerca in Oncologia di Precisione.<\/p>\n<\/td>\n<\/tr>\n

\u00a0<\/td>\n<\/tr>\n
\n

H. EVENTUALI INDICATORI ATTESTANTI L\u2019IMPATTO DESCRITTO<\/strong><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Indicatori di successo sono:<\/p>\n

-1- Elevato numero di pubblicazioni scientifiche<\/strong> del TOR (vedi sezione I-b)<\/p>\n

-2- Elevate citazioni ed H-index<\/strong> dopo-2015 dei principali componenti del TOR:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Melino:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 citazioni-2015=25732,\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 h-index-2015=65<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Piacentini:\u00a0\u00a0 citazioni-2015=20157,\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 h-index-2015=45<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Novelli:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 citazioni-2015=8408,\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 h-index-2015=43<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Candi:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 citazioni-2015=11349,\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 h-index-2015=35<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Agostini:\u00a0\u00a0\u00a0\u00a0\u00a0 citazioni-2015=3119,\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 h-index-2015=30<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Amelio:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 citazioni-2015=7857,\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 h-index-2015=25<\/p>\n

-3- Elevato numero di convegni e congressi<\/strong> scientifici del TOR (vedi sezione G)<\/p>\n

-4- Elevato impact factor delle riviste<\/strong> prodotte dal TOR (vedi sezione G)<\/p>\n

-5- Numero e qualit\u00e0 delle collaborazioni locali ed internazionali<\/strong> prodotte dal TOR (vedi sezione G)<\/p>\n<\/td>\n<\/tr>\n

\n

I. EVENTUALI PUBBLICAZIONI DI RIFERIMENTO DEL CASO STUDIO<\/strong><\/span><\/p>\n<\/td>\n<\/tr>\n

\u00a0<\/td>\n<\/tr>\n
\n

a) principali pubblicazioni scientifiche di riferimento a livello nazionale\/internazionale:<\/strong><\/span><\/p>\n

ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes.
Nature<\/strong>. 2020;578(7793):82\u201393. doi:10.1038\/s41586-020-1969-6<\/p>\n

Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive Characterization of Cancer Driver Genes and Mutations.
Cell<\/strong>. 2018;174(4):1034\u20131035. doi:10.1016\/j.cell.2018.07.034<\/p>\n

Liu J, Lichtenberg T, Hoadley KA, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell<\/strong>. 2018;173(2):400\u2013416.e11. doi:10.1016\/j.cell.2018.02.052<\/p>\n

Chen H, Li C, Peng X, et al. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
Cell<\/strong>. 2018;173(2):386\u2013399.e12. doi:10.1016\/j.cell.2018.03.027<\/p>\n

Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive Characterization of Cancer Driver Genes and Mutations.
Cell<\/strong>. 2018;173(2):371\u2013385.e18. doi:10.1016\/j.cell.2018.02.060<\/p>\n

Huang KL, Mashl RJ, Wu Y, et al. Pathogenic Germline Variants in 10,389 Adult Cancers.
Cell<\/strong>. 2018;173(2):355\u2013370.e14. doi:10.1016\/j.cell.2018.03.039<\/p>\n

Malta TM, Sokolov A, Gentles AJ, et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell<\/strong>. 2018;173(2):338\u2013354.e15. doi:10.1016\/j.cell.2018.03.034<\/p>\n

Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas.
Cell<\/strong>. 2018;173(2):321\u2013337.e10. doi:10.1016\/j.cell.2018.03.035<\/p>\n

Ding L, Bailey MH, Porta-Pardo E, et al. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
Cell<\/strong>. 2018;173(2):305\u2013320.e10. doi:10.1016\/j.cell.2018.03.033<\/p>\n

Hoadley KA, Yau C, Hinoue T, et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell<\/strong>. 2018;173(2):291\u2013304.e6. doi:10.1016\/j.cell.2018.03.022<\/p>\n

Kahles A, Lehmann KV, Toussaint NC, et al. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell<\/strong>. 2018;34(2):211\u2013224.e6. doi:10.1016\/j.ccell.2018.07.001<\/p>\n

Berger AC, Korkut A, Kanchi RS, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
Cancer Cell<\/strong>. 2018;33(4):690\u2013705.e9. doi:10.1016\/j.ccell.2018.03.014<\/p>\n<\/td>\n<\/tr>\n

\n

b) principali pubblicazioni scientifiche dell\u2019Istituzione o del Dipartimento\/i coinvolti:<\/strong><\/span><\/p>\n

Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses [published online, 2020 Mar 23].
Cell Death Differ<\/strong>. 2020;10.1038\/s41418-020-0530-3. doi:10.1038\/s41418-020-0530-3<\/p>\n

Panatta E, et al. Long non-coding RNA uc.291 controls epithelial differentiation by interfering with the ACTL6A\/BAF complex. EMBO Rep<\/strong>. 2020;21(3):e46734. doi:10.15252\/embr.201846734<\/p>\n

du Pr\u00e9 MF, Blazevski J, et al. B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2.
J Exp Med<\/strong>. 2020;217(2):e20190860.<\/p>\n

Di Rienzo M, Romagnoli A, Antonioli M, Piacentini M, Fimia GM. TRIM proteins in autophagy: selective sensors in cell damage and innate immune responses. Cell Death Differ<\/strong>. 2020;27(3):887\u2013902.<\/p>\n

Bernassola F, Chillemi G, Melino G. HECT-Type E3 Ubiquitin Ligases in Cancer. Trends Biochem Sci<\/strong>. 2019;44(12):1057\u20131075.<\/p>\n

Bufalieri F, Infante P, Bernardi F, et al. ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of \u03b2TrCP. Nature Commun<\/strong>. 2019;10(1):3304.<\/p>\n

Fedorova O, Petukhov A, Daks A, et al. Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis.
Oncogene<\/strong>. 2019;38(12):2108\u20132122.<\/p>\n

Paoletti A, Allouch A, Caillet M, et al. HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry. Cell Rep<\/strong>. 2019;28(13):3381\u20133394.e7.<\/p>\n

Amelio I, Mancini M, Petrova V, et al. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc Natl Acad Sci U S A<\/strong>. 2018;115(46):E10869\u2013E10878.<\/p>\n

Smirnov A, Lena AM, Cappello A, et al. ZNF185 is a p63 target gene critical for epidermal differentiation and squamous cell carcinoma development. Oncogene<\/strong>. 2019;38(10):1625\u20131638.<\/p>\n

Di Rienzo M, Piacentini M, Fimia GM. A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells. Autophagy<\/strong>. 2019;15(9):1674\u20131676.<\/p>\n

Di Rienzo M, Antonioli M, Fusco C, et al. Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains. Science Adv<\/strong>. 2019;5(5):eaau8857.<\/p>\n

Villella VR, Venerando A, Cozza G, et al. A pathogenic role for cystic fibrosis transmembrane conductance regulator in celiac disease. EMBO J.<\/strong>2019;38(2):e100101.<\/p>\n

Di Rita A, Peschiaroli A, D Acunzo P, et al. HUWE1 E3 ligase promotes PINK1\/PARKIN-independent mitophagy by regulating AMBRA1 activation via IKK\u03b1. Nature Commun<\/strong>. 2018;9(1):3755.<\/p>\n

Amelio I, Melino G. Similar Domains for Different Regulations of p53 Family. Structure<\/strong>. 2018;26(8):1047\u20131049.<\/p>\n

Marini A, Rotblat B, Sbarrato T, et al. TAp73 contributes to the oxidative stress response by regulating protein synthesis.
Proc Natl Acad Sci U S A<\/strong>. 2018;115(24):6219\u20136224.<\/p>\n

Melino G. Order must spring from chaos in Italian research. Nature<\/strong>. 2018;556(7702):436. doi:10.1038\/d41586-018-04896-6<\/p>\n

Sanarico AG, Ronchini C, Croce A, et al. The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. Leukemia<\/strong>. 2018;32(4):911\u2013919.<\/p>\n

D’Eletto M, Rossin F, Occhigrossi L, et al. Transglutaminase Type 2 Regulates ER-Mitochondria Contact Sites by Interacting with GRP75. Cell Rep<\/strong>. 2018;25(13):3573\u20133581.e4.<\/p>\n

Rossin F, Villella VR, D’Eletto M, et al. TG2 regulates the heat-shock response by the post-translational modification of HSF1.
EMBO Rep<\/strong>. 2018;19(7):e45067.<\/p>\n

Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ<\/strong>. 2018;25(3):486\u2013541.<\/p>\n

Noto A, De Vitis C, Pisanu ME, et al. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP\/TAZ. Oncogene<\/strong>. 2017;36(32):4671\u20134672.<\/p>\n

Raschell\u00e0 G, Melino G, Malewicz M. New factors in mammalian DNA repair-the chromatin connection.
Oncogene<\/strong>. 2017;36(33):4673\u20134681.<\/p>\n

Noto A, De Vitis C, Pisanu ME, et al. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP\/TAZ. Oncogene<\/strong>. 2017;36(32):4573\u20134584.<\/p>\n

Rada M, Vasileva E, Lezina L, et al. Human EHMT2\/G9a activates p53 through methylation-independent mechanism.
Oncogene<\/strong>. 2017;36(7):922\u2013932.<\/p>\n

Inoue S, Li WY, Tseng A, et al. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. Cancer Cell<\/strong>. 2016;30(2):337\u2013348.<\/p>\n

Amelio I, Melino G. Damage limitation. Elife<\/strong>. 2016;5:e17394.<\/p>\n

Chillemi G, Kehrloesser S, Bernassola F, et al. Structural Evolution and Dynamics of the p53 Proteins.
Cold Spring Harb Perspect Med<\/strong>. 2017;7(4):a028308.<\/p>\n

Galluzzi L, Baehrecke EH, Ballabio A, et al. Molecular definitions of autophagy and related processes.
EMBO J.<\/strong> 2017;36(13):1811\u20131836.<\/p>\n

Antonioli M, Di Rienzo M, Piacentini M, Fimia GM. Emerging Mechanisms in Initiating and Terminating Autophagy.
Trends Biochem Sci<\/strong>. 2017;42(1):28\u201341. doi:10.1016\/j.tibs.2016.09.008<\/p>\n

Faccenda D, Nakamura J, Gorini G, et al. Control of Mitochondrial Remodeling by the ATPase Inhibitory Factor 1 Unveils a Pro-survival Relay via OPA1. Cell Rep<\/strong>. 2017;18(8):1869\u20131883.<\/p>\n

Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy<\/strong>. 2016;12(1):1\u2013222.<\/p>\n

D’Abramo M, Be\u0161ker N, Desideri A, Levine AJ, Melino G, Chillemi G. The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain. Oncogene<\/strong>. 2016;35(25):3272\u20133281.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>","protected":false},"excerpt":{"rendered":"

link al sito www.centrotor.uniroma2.it \u00a0 TITOLO: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Torvergata Oncoscience Research (TOR) \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 CAMPO D\u2019AZIONE:\u00a0\u00a0\u00a0 Public Engagement (g) + Sperimentazione Clinica e Tutele della Salute (e) + Open<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1738","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www-2026.medsper.uniroma2.it\/index.php?rest_route=\/wp\/v2\/pages\/1738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www-2026.medsper.uniroma2.it\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www-2026.medsper.uniroma2.it\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www-2026.medsper.uniroma2.it\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www-2026.medsper.uniroma2.it\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1738"}],"version-history":[{"count":0,"href":"https:\/\/www-2026.medsper.uniroma2.it\/index.php?rest_route=\/wp\/v2\/pages\/1738\/revisions"}],"wp:attachment":[{"href":"https:\/\/www-2026.medsper.uniroma2.it\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}